艾达赛珠单抗（Praxbind）逆转直接凝血酶抑制剂达比加群作用的证据：RE-VERSE AD全队列分析后的综述
Evidence for Idarucizumab (Praxbind) in the Reversal Of the Direct Thrombin Inhibitor Dabigatran: Review Following the RE-VERSE AD Full Cohort Analysis.
作者信息
Hutcherson Timothy C, Cieri-Hutcherson Nicole E, Bhatt Rajvi
出版信息
P T. 2017 Nov;42(11):692-698.
Abstract
Idarucizumab is the first reversal agent approved for the direct thrombin inhibitor dabigatran. The authors summarize the findings from the clinical trial series and describe case reports, post-marketing data, and ongoing studies.
摘要
依达赛珠单抗是首个被批准用于直接凝血酶抑制剂达比加群的逆转剂。作者总结了临床试验系列的结果，并描述了病例报告、上市后数据和正在进行的研究。
相似文献
1
2
Idarucizumab: A Review as a Reversal Agent for Dabigatran.依达赛珠单抗：作为达比加群逆转剂的综述。
Am J Cardiovasc Drugs. 2016 Aug;16(4):297-304. doi: 10.1007/s40256-016-0181-4.
3
Idarucizumab for Reversal of Dabigatran-Associated Anticoagulation.依达赛珠单抗用于逆转达比加群相关抗凝作用
Ann Pharmacother. 2016 Oct;50(10):847-54. doi: 10.1177/1060028016659504. Epub 2016 Jul 7.
4
[More safe anticoagulant treatment - use of idarucizumab (Praxbind®): case reports from RE-VERSE AD study and clinical practice].
Vnitr Lek. 2018 Spring;64(3):309-313.
5
Idarucizumab for Dabigatran Reversal in the Management of Patients With Gastrointestinal Bleeding.达比加群酯逆转剂依达鲁珠单抗在胃肠道出血患者管理中的应用。
Circulation. 2019 Feb 5;139(6):748-756. doi: 10.1161/CIRCULATIONAHA.118.036710.
6
Idarucizumab (PRAXBIND®) as a sole reversal agent in an unstable hemorrhagic shock patient on an unknown anticoagulant with elevated protime/international normalized ratio (PT/INR).依达鲁珠单抗（派安普利）作为单一逆转剂在不明抗凝剂合并凝血酶原时间/国际标准化比值（PT/INR）升高的不稳定型出血性休克患者中的应用。
Am J Emerg Med. 2021 Aug;46:800.e1-800.e3. doi: 10.1016/j.ajem.2021.01.086. Epub 2021 Feb 6.
7
Lessons learnt from local real-life experience with idarucizumab for the reversal of dabigatran.从达比加群酯逆转剂依达鲁珠单抗的本地真实世界经验中吸取的教训。
Intern Med J. 2019 Jan;49(1):59-65. doi: 10.1111/imj.13995.
8
Dabigatran Reversal With Idarucizumab in Patients Requiring Urgent Surgery: A Subanalysis of the RE-VERSE AD Study.达比加群酯逆转剂依达鲁单抗用于需紧急手术的患者：RE-VERSE AD 研究的亚组分析。
Ann Surg. 2021 Sep 1;274(3):e204-e211. doi: 10.1097/SLA.0000000000003638.
9
Dabigatran Reversal With Idarucizumab in Patients With Renal Impairment.达比加群酯逆转剂依达鲁单抗在肾功能损害患者中的应用。
J Am Coll Cardiol. 2019 Oct 8;74(14):1760-1768. doi: 10.1016/j.jacc.2019.07.070.
10
Idarucizumab for Reversing Dabigatran-Induced Anticoagulation: A Systematic Review.达比加群酯拮抗剂依达鲁珠单抗逆转抗凝作用的系统评价。
Am J Ther. 2018 May/Jun;25(3):e333-e338. doi: 10.1097/MJT.0000000000000460.
引用本文的文献
1
Dabigatran in cardiovascular disease management: A comprehensive review.达比加群酯在心血管疾病管理中的应用：一项综述
World J Cardiol. 2021 Dec 26;13(12):710-719. doi: 10.4330/wjc.v13.i12.710.
2
Therapeutic strategies for thrombosis: new targets and approaches.血栓治疗策略：新靶点和新方法。
Nat Rev Drug Discov. 2020 May;19(5):333-352. doi: 10.1038/s41573-020-0061-0. Epub 2020 Mar 4.
3
Current status of oral anticoagulant reversal strategies: a review.口服抗凝剂逆转策略的现状：综述
Ann Transl Med. 2019 Sep;7(17):411. doi: 10.21037/atm.2019.07.101.
本文引用的文献
1
Reversal of the Anticoagulation Effects of Dabigatran Etexilate by Idarucizumab in Three Patients Needing Urgent Surgical Intervention and One Case of Intravenous Thrombolysis in Ischaemic Stroke.依达赛珠单抗逆转达比加群酯在三名需要紧急手术干预患者及一例缺血性卒中静脉溶栓患者中的抗凝作用。
Eur J Case Rep Intern Med. 2017 Feb 14;4(4):000569. doi: 10.12890/2017_000569. eCollection 2017.
2
Incomplete dabigatran reversal with idarucizumab.达比加群酯逆转剂idarucizumab 作用不完全。
Clin Toxicol (Phila). 2018 Mar;56(3):216-218. doi: 10.1080/15563650.2017.1349911. Epub 2017 Jul 13.
3
Idarucizumab (Praxbind) for reversal of pradaxa prior to emergent repair of contained ruptured transverse arch aneurysm.依达赛珠单抗（Praxbind）用于在急诊修复包含性破裂横弓动脉瘤之前逆转达比加群的作用。
Ann Card Anaesth. 2017 Jul-Sep;20(3):369-371. doi: 10.4103/0971-9784.210426.
4
First Reported Case of Hemopericardium Related to Dabigatran Use Reversed by New Antidote Idarucizumab.首例与达比加群使用相关的心包积血病例被新型解毒剂依达赛珠单抗逆转。
Case Rep Cardiol. 2017;2017:6458636. doi: 10.1155/2017/6458636. Epub 2017 Jun 14.
5
Idarucizumab for Dabigatran Reversal - Full Cohort Analysis.达比加群酯逆转剂依达鲁珠单抗：全队列分析。
N Engl J Med. 2017 Aug 3;377(5):431-441. doi: 10.1056/NEJMoa1707278. Epub 2017 Jul 11.
6
Intravenous Fibrinolysis in Ischemic Stroke of Large Vessel after Reversing Effect of Dabigatran with Idarucizumab.使用依达赛珠单抗逆转达比加群的作用后对大血管缺血性卒中进行静脉溶栓治疗
J Stroke Cerebrovasc Dis. 2017 Sep;26(9):e192-e193. doi: 10.1016/j.jstrokecerebrovasdis.2017.04.032. Epub 2017 Jun 26.
7
Dabigatran Reversal in a Patient With End-Stage Liver Disease and Acute Kidney Injury.达比加群酯逆转终末期肝病合并急性肾损伤患者的出血事件。
Am J Kidney Dis. 2018 Jan;71(1):137-141. doi: 10.1053/j.ajkd.2017.03.025. Epub 2017 May 24.
8
Antagonizing dabigatran by idarucizumab in cases of ischemic stroke or intracranial hemorrhage in Germany - A national case collection.德国缺血性卒中或颅内出血情况下idarucizumab拮抗达比加群的病例收集 - 一项全国性病例收集。
Int J Stroke. 2017 Jun;12(4):383-391. doi: 10.1177/1747493017701944. Epub 2017 Mar 24.
9
Systemic Thrombolysis in Acute Ischemic Stroke after Dabigatran Etexilate Reversal with Idarucizumab-A Case Report.使用依达赛珠单抗逆转达比加群酯后急性缺血性卒中的全身溶栓治疗——病例报告
J Stroke Cerebrovasc Dis. 2017 Jul;26(7):e123-e125. doi: 10.1016/j.jstrokecerebrovasdis.2017.03.039. Epub 2017 May 4.
10
Late rebound of dabigatran levels after idarucizumab reversal in two patients with severe renal failure.两名严重肾衰竭患者使用艾达赛珠单抗逆转后达比加群水平的晚期反弹。
Eur J Anaesthesiol. 2017 Jun;34(6):400-402. doi: 10.1097/EJA.0000000000000617.
Zotero 插件